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ABSTRACT
Background: Epstein Barr virus (EBV) has been suspected of being involved in the development of atopy.
There are several studies suggesting a positive as well as negative association between EBV infection and
atopic diseases. Here, we carried out a large-scale, systematic investigation to address the issue of the possi-
ble association between EBV infection and atopic diseases.
Methods: Anti-EBV-viral capsid antigen (VCA) antibody titer, anti-EBV nuclear antigen (EBNA) antibody titer,
atypical lymphocyte (AtLy) count and EBV-DNA copy number in 106 WBC were examined as evidence for EBV
infection, and characteristic parameters of atopic disease such as total serum immunoglobulin E (IgE) level,
highest antigen-specific IgE antibody titer (h-RAST) and peripheral blood eosinophil (Eos) count were meas-
ured and compared among atopic subjects and non-atopic controls, and correlations between parameters of
atopy and EBV infection were subjected to statistical analysis.
Results: Anti-EBV, in particular anti-EBNA antibody titer and AtLy count in peripheral blood were markedly
higher in patients with bronchial asthma (BA) andor atopic dermatitis (AD) than in non-atopic controls, espe-
cially in early childhood. No similar findings were obtained for antibodies to cytomegalovirus (CMV). EBV-DNA
copy numbers in WBC were elevated in atopic subjects. Correlations between EBV-DNA copy number and
other parameters of EBV infection (anti-EBV antibody titer and AtLy count) but those with cytomegalovirus
(CMV) infection and markers of atopic disease (IgE, h-RAST level, and Eos count) were demonstrated. It was
found that anti-EBNA seronegative atopics have higher copy numbers of EBV DNA in WBC and more elevated
levels of IgE and h-RAST than anti-EBNA seropositive atopics. Anti-EBV VCA antibody titer in individuals aged
15 years and younger and anti-EBNA antibody titer among Japanese were suggested to have declined consid-
erably in the past 15 years.
Conclusions: The present study suggests that EBV infection in early childhood could precipitate atopic dis-
eases.
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INTRODUCTION
In the past several decades, the prevalence of atopic
diseases has rapidly increased, especially in so-called
developed countries. Of the viruses thought to play a
role in the development of atopy, Epstein Barr virus
(EBV) is particularly worthy of attention.1,2 EBV in-
fection mainly takes place in the first year of life, and
more commonly develops in younger people in so-
called developing countries.3
Nordbring et al. 4 and Bahna et al. 5 described an
elevation of serum immunoglobulin E ( IgE) during
acute EBV infection, although this was not confirmed
by a more recent study.6 Olson et al.7 reported a high
frequency of IgE-mediated allergic disease in chronic
mononucleosis syndrome , which is thought to be
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caused by EBV. There are several studies suggesting
a positive as well as negative association between ele-
vated EBV antibodies and atopic diseases.1,2,4-11
Therefore, we carried out a large-scale study. In
this investigation, in addition to serum IgE level, h-
RAST and peripheral blood Eos count were employed
as markers of atopic manifestation . As markers of
preceding EBV infection, anti-EBV viral capsid anti-
gen (VCA) antibody1,2 and anti-EBV nuclear antigen
(EBNA) antibody, peripheral blood atypical lympho-
cyte (AtLy) count and finally, EBV-DNA copy num-
bers in 106 WBC (EBV-DNA) were employed．
METHODS
SUBJECTS
Japanese people living in the Tokyo area (Kanto dis-
trict ) who attended the institutes to which the
authors of this report belong and were referred to the
Department of Allergy and Rheumatology of The Uni-
versity of Tokyo were enrolled in the present study.
Blood samples of bronchial asthma ( BA ) andor
atopic dermatitis (AD) patients were obtained when
their diseases were well controlled and stable. The
control subjects were healthy age-matched individu-
als who attended the institutes for health check, vac-
cination or preoperative examination before minor
surgery. A diagnosis of BA was made according to
the criteria of the National Institutes of Health, USA
with slight modification.12 Patients with AD, fulfilling
the criteria of Hannifin and Rajka,13 took part in the
study. When several atopic diseases coexisted in an
individual, the patient was included in an appropriate
disease group according to hisher chief complaints.
This study was approved by the Committee for the
Protection of the Rights of Human Subjects of the
University of Tokyo, Graduate School of Medicine.
Written informed consent was obtained from the sub-
jects themselves or from their parents in the case of
minors.
All atopic subjects had an elevated total IgE level
( > 160 IUml ) and allergen-specific IgE antibody
(ies) h-RAST； (>0.70 UAml) to at least one of the
following allergens : house dust mite (Dermato-
phagoides farinae , Dermatophagoides pteronyssinus) ,
Japanese cedar pollen, cat and dog dander. Children
aged ten years or below were also examined for IgE
antibodies to egg white , cow’s milk and soy bean,
which are the major food allergens in Japan. Clini-
cally non-atopic individuals with no history of atopic
disease (AD, BA, allergic rhinitis, rhinoconjunctivitis,
or urticaria) and no symptoms of atopic disease upon
examination by at least one of the investigators, but
with an elevated serum IgE (>160 IUml ) and clearly
positive h-RAST (>0.70 UAml) were classified as as-
ymptomatic atopic subjects (Asym). The normal con-
trol subjects (Normal) were healthy individuals with
no symptoms or history of AD, BA or other atopic dis-
ease , low IgE level (160 IUml ) , and negative
RAST (<0.35 UAml )．
AGE MATCHING
Age matching was statistically checked to confirm
that the inter-group age-difference was not signifi-
cant. When a sufficient number of blood samples was
available, more strict age matching was performed in
which patientcontrol pairs whose age difference was
less than one year (in the case of subjects aged 5 or
under , less than 6 months) were selected and the
most suitable pairs were enrolled in the study．
ANTI-VIRAL ANTIBODY TITERS
Anti-EBV VCA IgG , IgM and anti-EBNA were as-
sayed by a fluorescent antibody (FA) technique . 14
Anti-EBV VCA IgM antibody titer measured by the
FA method was below the detection limit in all cases,
and were not subjected to analysis. There were no
significant gender differences in anti-EBV antibody
titers (anti-EBV VCA ; P = 0.185ns, anti-EBNA ; P =
0.200ns; Mann-Whitney U-test) . Anti-CMV IgG and
IgM were examined using enzyme-linked immuno-
sorbent assay ( ELISA ) according to the manufac-
turer’s protocol (Denka Seiken, Tokyo, Japan)．
MEASUREMENT OF TOTAL SERUM IGE LEVEL
AND ANTIGEN-SPECIFIC IGE ANTIBODY TITER
Total serum IgE level and h-RAST titers were deter-
mined using a Pharmacia CAP-RAST System
(Uppsala, Sweden)．
ANALYSIS OF LEUKOCYTES
Cytologic examination of peripheral WBC was per-
formed using May GrÜnwald Giemsa stain. The rela-
tive proportions of the various leukocyte subpopula-
tions were determined by differential cell counting of
1000 cells.
EBV-DNA COPY NUMBER IN 106 WBC
EBV-DNA in 106 WBC was quantified using a real-
time RT-PCR assay.15
DATA ANALYSIS
Data were analyzed using SPSS (SPSS Inc . , Chi-
cago, IL, USA). The titers of anti-EBV (anti-VCA and
anti-EBNA) antibodies, serum total IgE level h-RAST,
Eos count and AtLy count were confirmed to distrib-
ute normally after logarithmic transformation. Geo-
metric means (GM) and standard deviations (SD)
were obtained after logarithmic transformation. The
age of enrolled subjects was expressed as arithmetic
means (AM)±standard errors of the mean (SEM) .
The non-parametric Mann-Whitney U -test was used
for inter-group comparisons . Correlations between
two parameters were examined by Kendall’s τ-test .
Statistical significance was expressed by symbols :
＊＊＊ = highly significant (P < 0.001), ＊＊ = highly sig-
nificant (P < 0.01), ＊ = significant (P < 0.05),†= not sig-
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Table 1 Comparison of markers of EBV infection and atopic manifestations in diferent age groups
(1)―4 (years)
Eosh-RASTIgEAtLyAnti-EBNAAnti-EBV VCAAge
N
GM ± SDGM ± SDGM ± SDGM ± SDGM ± SDGM ± SDAM ± SEM
2.26 ± 0.61-0.02 ± 0.661.56 ± 0.711.61 ± 0.580.77 ± 0.210.85 ± 0.322.25 ± 0.498Healthy
　vs
0.83 ± 0.191.70 ± 0.582.58 ± 0.451.77 ± 0.751.18 ± 0.551.75 ± 0.793.00 ± 0.3710BA/AD patients
0.006＊＊0.001＊＊0.006＊＊0.574ns0.035＊0.020＊0.259nsP (two tailed)
(2) 5―15 (years)
Eosh-RASTIgEAtLyAnti-EBNAAnti-EBV VCAAge
N
GM ± SDGM ± SDGM ± SDGM ± SDGM ± SDGM ± SDAM ± SEM
1.88 ± 0.400.17 ± 0.921.69 ± 0.651.30 ± 0.000.93 ± 0.371.28 ± 0.749.25 ± 0.7012Healthy
　vs
2.70 ± 0.181.78 ± 0.492.91 ± 0.491.49 ± 0.471.15 ± 0.471.35 ± 0.569.67 ± 0.7312BA/AD patients
0.000＊＊＊0.000＊＊＊0.000＊＊＊0.149ns0.210ns0.436ns0.661nsP (two tailed)
(3) 16―30 (years)
Eosh-RASTIgEAtLyAnti-EBNAAnti-EBV VCAAge
N
GM ± SDGM ± SDGM ± SDGM ± SDGM ± SDGM ± SDAM ± SEM
2.04 ± 0.290.10 ± 0.761.67 ± 0.531.30 ± 0.001.14 ± 0.32 1.92 ± 0.4322.1 ± 1.2917Healthy 
　vs
2.84 ± 0.211.96 ± 0.463.08 ± 0.621.31 ± 0.021.23 ± 0.381.92 ± 0.6422.2 ± 1.2917BA/AD patients
0.000＊＊＊0.000＊＊＊0.000＊＊＊0.317ns0.474ns0.710ns0.890nsP (two tailed)
(4) 31―45 (years)
Eosh-RASTIgEAtLyAnti-EBNAAnti-EBV VCAAge
N
GM ± SDGM ± SDGM ± SDGM ± SDGM ± SDGM ± SDAM ± SEM
1.82 ± 0.390.25 ± 0.811.86 ± 0.501.30 ± 0.001.11 ± 0.282.09 ± 0.3636.6 ± 1.538Healthy 
　vs
2.70 ± 0.392.18 ± 1.233.30 ± 0.991.30 ± 0.001.49 ± 0.222.09 ± 0.2236.4 ± 1.518BA/AD patients
0.002＊＊0.008＊＊0.016＊1.000ns0.014＊0.749ns0.784nsP (two tailed)
(5) 46―(years)
Eosh-RASTIgEAtLyAnti-EBNAAnti-EBV VCAAge
N
GM ± SDGM ± SDGM ± SDGM ± SDGM ± SDGM ± SDAM ± SEM
2.04 ± 0.39-0.23 ± 0.691.79 ± 0.741.30 ± 0.001.18 ± 0.252.11 ± 0.5963.0 ± 3.5610Healthy
　vs
2.58 ± 0.220.74 ± 0.912.35 ± 0.491.44 ± 0.301.27 ± 0.391.93 ± 1.4862.9 ± 3.5410BA/AD patients
0.002＊＊0.024＊0.031＊0.147ns0.479ns0.538ns0.939nsP (two tailed)
nificant (P < 0.1), ns = not significant (P> 0.1)．
RESULTS
ANTI-EBV, ESPECIALLY ANTI-EBNA ANTIBODY
TITERS ARE ELEVATED IN ATOPIC PATIENTS
In the first set of studies , anti-EBV antibody titers
were measured in blood samples from 204 individuals
(52 Normal, 40 Asympt, 58 BA and 54 AD)．
The non-parametric Mann-WhitneyU-test for strictly
age-matched inter-group (healthy = NormalAsym vs
BAAD) comparison of anti-EBV antibody levels in all
subjects 1 or in anti-EBV seropositive individuals 2
were carried out . No statistically significant differ-
ence in anti-EBV VCA titer was detected between
healthy and atopic (BAAD) patients (P0.099), but
anti-EBNA titer was considerably elevated in atopic
patients ( all subjects : P = 0.010＊, EBV seroposi-
tives : P = 0.020＊)．
INTER-GROUP COMPARISON OF PARAMETERS
OF EBV INFECTION AND ATOPIC MANIFESTA-
TION IN DIFFERENT AGE GROUPS
Characteristic parameters of EBV infection (anti-EBV
VCA , anti-EBNA , AtLy ) and atopic manifestations
(IgE, h-RAST, Eos) at different ages were compared
in healthy and atopic (BAAD) subjects. As shown in
Table 1, IgE, h-RAST and Eos in the atopic (BAAD)
groups were significantly higher than those in the
healthy groups in all age groups tested. A rise of anti-
EBV VCA and anti-EBNA in atopic (BAAD) patients
compared with healthy subjects was observed clearly
in subjects aged 4 years or younger．
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Table 2 Corelation between markers of EBV infection and atopic manifestations
Eosh-RASTIgE
 0.048 0.073 0.123Corelation coeficient
Anti-EBV VCA  0.536ns 0.365ns 0.109nsP value (two tailed)
 90 90 90N
 0.213 0.178 0.182Corelation coeficient
Anti-EBNA  0.006＊＊ 0.029＊ 0.019＊P value (two tailed)
 90 90 90N
 0.144＊ 0.123 0.097Corelation coeficient
AtLy  0.092† 0.171ns 0.256nsP value (two tailed)
 90 90 90N
In the course of the study, we noticed that healthy
(clinically non-atopic) subjects are not always non-
atopic serologically ; that is, they could be hyper-IgE
responsive andor hyper-eosinophilic . Therefore ,
they were grouped as asymptomatic (Asym : clini-
cally non-atopic but serologically atopic), while sub-
jects who are non-atopic both clinically and serologi-
cally were grouped as Normal. With the new group-
ing, a rise of anti-EBV VCA antibody titer in atopics
seemed to become more evident (Healthy vs BAAD
patients : P = 0.610ns, Normal vs Atopics = AsymBA
AD : P = 0.078†)．
CORRELATION BETWEEN PARAMETERS OF
EBV INFECTION AND ATOPIC MANIFESTATION
Parameters of previous EBV exposure ( anti-EBV
VCA and anti-EBNA antibodies, AtLy) and character-
istic markers of atopic disease (IgE, h-RAST, Eos)
were examined(Table 2). Significant correlation was
often observed between markers of previous EBV in-
fection and markers of atopic manifestation, further
suggesting a close association between EBV infection
and the development of atopic diseases.
EBV-DNA COPY NUMBER IN WBC AND ANTI-
CMV IN ATOPIC SUBJECTS AND NORMAL CON-
TROLS
In the second set of studies , individuals were re-
cruited and in addition to the factors examined in the
above studies, EBV-DNA copy number106 WBC and
anti-CMV antibody levels were assayed．
Inter-group comparison between 11 normal con-
trols and 11 strictly age-matched atopic subjects
(AsymBAAD) was carried out. As shown in Ta-
ble 3,EBV-DNA copy numbers in WBC were clearly
increased in atopic subjects compared with normal
controls (P = 0.002＊＊) . Anti-EBV VCA and anti-
EBNA antibody levels were higher in atopic subjects
(P = 0.039＊ and P = 0.067†, respectively), while anti-
CMV IgG and IgM were not significantly different be-
tween atopic subjects and normal controls (P = 0.469ns
and P = 0.843ns, respectively)．
CORRELATION BETWEEN EBV-DNA IN WBC
AND MARKERS OF ATOPY OR VIRAL ( EBV
CMV) INFECTION
The correlation between markers of atopy (IgE, h-
RAST and Eos) and markers of viral (EBVCMV) in-
fection was examined in 58 unselected and in 33 EBV
seropositive subjects and the results are shown in Ta-
ble 4.
In the unselected population, moderate correlation
between EBV DNA and atopic markers ( IgE : P =
0.019＊, h-RAST : P = 0.055†, Eos : P = 0.062†) was
observed, while its correlation with markers of EBV
infection seemed more significant ( anti-EBV
VCA : P = 0.021＊, anti-EBNA : P = 0.048＊). In EBV
seropositive subjects , the correlation between EBV
DNA and atopic marker was more evident (IgE : P =
0.021＊, h-RAST : P = 0.038＊ and Eos : P = 0.028＊),
while correlation between anti-EBV antibody titers
was less clear ( anti-EBV VCA : P = 0.250ns, anti-
EBNA : P = 0.024＊). In both subject groupings, EBV
DNA never correlated with anti-CMV antibody levels
(P > 0.1ns). Such findings strongly suggest that the in-
creased anti-viral antibody titer in atopic patients was
specific for EBV．
ANTI-EBNA NEGATIVE ATOPICS HAVE HIGHER
EBV DNA IN WBC AND HIGHER HYPER-IGE RE-
SPONSIVENESS THAN ANTI-EBNA POSITIVE
ATOPICS
Subsequently, various markers were compared in 18
anti-EBNA negative and 24 anti-EBNA positive atop-
ics (AsymBAAD) aged 5 to 38 years. It was found
that all (N = 14) anti-EBV VCA negative subjects were
also anti-EBNA negative. As shown in Table 5, anti-
EBNA negative atopic subjects had higher numbers
of EBV DNA copies in WBC, and higher levels of IgE
and h-RAST than anti-EBNA positive atopics suggest-
ing that their previous EBV load was heavier com-
pared with anti-EBNA positive atopics．
AGE DISTRIBUTION OF ANTI-EBV ANTIBODIES
IN HEALTHY INDIVIDUALS IN 2002 COMPARED
WITH THAT IN 1987
Anti-EBV VCA and anti-EBNA titers of clinically
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Fig. 1　Comparison of anti-EBV antibodies in Japanese 
healthy individuals in 2002 and in 1987. (a) Anti-EBV VCA 
antibody. (b) Anti-EBNA antibody. GM ± SEM are ploted 
against age. Anti-EBV-VCA and anti-EBNA antibody titers in 
2002 and 1987 are represented as closed and open sym-
bols, respectively.
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healthy (non-atopic) individuals obtained in the pre-
sent (2002) study were plotted against age and com-
pared with the Japanese data reported in 1987.16 The
methods of anti-EBV VCA and anti-EBNA titration
were exactly the same (FA) in the two studies. Nei-
ther the exact number (N) nor SD of the data of the
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Table 4 Corelation between EBV DNA in WBC and markers of atopy or viral (EBV / CMV) infection 
(1) unselected population
Anti-CMV 
IgM
Anti-CMV 
IgG
Eos h-RASTIgE Anti-EBNA
Anti-EBV 
VCA
 0.075 0.176 0.203 0. 207 0.245 0.231 0.266Corelation
Coeficient
EBV DNA  0.478ns 0.111ns 0.062† 0.055† 0.019＊ 0.048＊ 0.021＊P value
(two tailed)
 58 58 54 57 58 56 56N
(2) EBV seropositive subjects
Anti-CMV 
IgM
Anti-CMV 
IgG
Eos h-RASTIgE Anti-EBNA
Anti-EBV 
VCA
 0.005 -0.003 0.302 0.297 0.318 0.407 0.183Corelation
Coeficient
EBV DNA  0.969ns 0.984ns 0.028＊ 0.038＊ 0.021＊ 0.024＊ 0.250nsP value
(two tailed)
 33 33 33 33 33 23 28N
1987 survey are available at present, but, since the
scale of the survey was very large (total N = 1086 and
each age group contained more than 60 samples) ,
one sample τ-test was carried out using the GM of
each age group in the 1987 survey as a test value. As
shown in Figure 1(a), anti-EBV VCA titer in subjects
before adolescence was lower in 2002 than in 1987,
while anti-EBNA titers surveyed in 2002 were consid-
erably lower in all age groups examined than those
surveyed in 1987(Fig. 1(b)).
DISCUSSION
EBV, a B lymphocytotropic herpesvirus, is associated
with several benign and malignant diseases . Most
people become latently infected with the virus before
adulthood . 17 Seroconversion in adults is rare , and
about 5% of adults remain seronegative for life (EBV-
non-seroconverters)．
Infectious mononucleosis (IM) is an acute and usu-
ally self-limiting lymphoproliferative disease caused
mostly by primary EBV infection.14,18 The hallmark of
acute IM is appearance of AtLy in the peripheral
blood. IgE level is increased mostly during the initial
stage of IM, and at that time, a strong correlation is
noted between the IgE response and the number of
circulating AtLy.5
In 1981, it was reported that seropositive children
aged 5 to 18 years with atopy have higher serum lev-
els of anti-EBV VCA antibody than non-atopic chil-
dren of similar ages. The increase in EBV VCA titer
was most pronounced in children with asthma (BA).1
This observation was confirmed in adults with atopic
eczema (AD) by the same group.2
On the basis of the well-known finding that EBV al-
most selectively infects B lymphocytes and induces
hyperproduction of immunoglobulins , it has been
strongly suspected that EBV infection may result in
an aberrant IgE response to any antigen and in this
way may precipitate atopic diseases.1,2 However, the
results of a recent study showing a higher prevalence
of high IgE levels in EBV-seronegative children ap-
pear to be inconsistent with the above hypothesis.6
This apparent discrepancy has never been re-
evaluated until now. Thus, we carried out an investi-
gation employing recent technology and advanced
computer software for statistical analysis . In this
study, in addition to the inter-group comparison of
anti-EBV VCA antibody titers between atopic patients
and healthy individuals, the correlation between pa-
rameters that reflect previous EBV exposure (EBV
DNA copy number in WBC , anti-EBNA , anti-EBV
VCA antibody titers and AtLy count in blood) and
markers associated with atopic disease (serum total
IgE, h-RAST level and Eos count in blood) were ex-
amined．
It was found that anti-EBV VCA titer was not ele-
vated in atopic (BAAD) patients compared with age-
matched healthy individuals ; however , anti-EBNA
antibody titer was markedly increased in atopic sub-
jects compared with healthy (clinically non-atopic) in-
dividuals (Table 6).
An elevated anti-EBV VCA antibody titer in atopic
subjects became evident when EBV-seropositive atop-
ics (AsymBAAD) were compared with normal con-
trol subjects (Table 6).
Inter-group comparison of parameters of atopic
manifestation and EBV infection in different age
groups, carried out subsequently, demonstrated that
a rise of anti-EBV VCA and anti-EBNA in atopic sub-
jects (BAAD) compared with healthy subjects was
observed most clearly in individuals aged 4 years or
younger(Table 1). These data suggest that EBV in-
fection in childhood increases the risk of develop-
ment of atopic diseases (BAAD)．
Correlation between parameters of previous EBV
exposure (anti-EBV VCA and anti-EBNA antibodies,
AtLy) and characteristic markers of atopic disease
(IgE, h-RAST, Eos) were examined and the results
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are summarized in Table 2. The clear correlation be-
tween markers of previous EBV infection and mark-
ers of atopic manifestation further suggests a close
association between EBV infection and the develop-
ment of atopic diseases.
Such findings were in agreement with the results
shown in Tables 4, 5, which demonstrated that anti-
EBV antibodies , but not anti-CMV antibody titers ,
were significantly different between the normal and
atopic subjects (AsymBAAD) and no significant
correlation was found between anti-CMV antibody
levels and parameters of atopy (IgE, h-RAST). Fur-
thermore, there was no statistically significant corre-
lation between anti-EBV and anti-CMV antibody tit-
ers. These results suggest that an assumed link be-
tween atopic manifestation and EBV infection is spe-
cific for EBV infection, and is not merely a reflection
of viral infection in general．
As shown in Table 3 in which normal controls and
atopics (AsymBAAD) were compared for anti-EBV
VCA (P = 0.039＊), anti-EBNA (P = 0.067†) and atopic
markers (IgE : P = 0.000＊＊＊, h-RAST : P = 0.000
＊＊＊, Eos : P = 0.001＊＊), EBV DNA copy numbers
in WBC were clearly elevated (P = 0.002＊＊) in the
atopics．
It was a kind of mystery to find that mean anti-EBV
antibody levels were higher in atopics than controls,
but on the other hand, many EBV seronegative atopic
(BAAD) patients whose anti-EBV antibody levels are
clearly lower than those in normal subjects do exist．
Helminen et al. reported a study of the resistance
to EBV infection, and speculated that the persistent
seronegativity of some adults may be explained by
eradication of the virus at the beginning of infec-
tion.19
However, this speculation seemed not to be com-
patible with the results shown in Table 5, which dem-
onstrated that anti-EBNA seronegative atopics have
higher copy numbers of EBV DNA in WBC and more
elevated levels of IgE and h-RAST than anti-EBNA se-
ropositive atopics．
The reality of anti-EBV (especially anti-EBNA) non-
seroconversion may be an immunological unrespon-
siveness which abrogates possibly protective anti-
EBNA antibody responses needed for limiting symp-
tomatic EBV infection to make anti-EBNA non-
seroconverters more sensitive to atopic diseases
(BAAD)(Table 5).
In 1969, Hinuma and colleagues examined the age
distribution of anti-EBV antibody in Japanese, and re-
ported that the prevalence of seropositivity was con-
siderably high in infancy and persisted for life.20
Anti-EBNA antibody titer in Japanese individuals
and anti-EBV VCA IgG antibody titer in childhood are
suggested to have decreased over the past 15 years
(Fig. 1).If low anti-EBV antibody titers in early child-
hood are a considerable risk factor for symptomatic
EBV infection, and if EBV is actually associated with
atopic diseases, this may explain why atopic patients
have abruptly increased recently in Japan as well as
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Table 6 Anti-EBV antibody titers, especialy anti-EBNA, are elevated in atopic patients
(1) Al subjects
Eosh-RASTIgEAtLyAnti-EBNAAnti-EBV VCAAge
N
GM ± SDGM ± SDGM ± SDGM ± SDGM ± SDGM ± SDAM ± SEM
1.97 ± 0.38-0.02 ± 0.721.67 ± 0.611.30 ± 0.001.10 ± 0.331.81 ± 0.6330.4 ± 3.1345Healthy
　vs
2.76 ± 0.261.66 ± 0.932.90 ± 0.721.45 ± 0.421.30 ± 0.391.92 ± 0.5530.4 ± 3.1145BA/AD patients
0.000＊＊＊0.000＊＊＊0.000＊＊＊0.006＊＊0.010＊0.610ns0.994nsP (two tailed)
(2) EBV-seropositive subjects
Eosh-RASTIgEAtLyAnti-EBNAAnti-EBV VCAAge
N
GM ± SDGM ± SDGM ± SDGM ± SDGM ± SDGM ± SDAM ± SEM
1.93 ± 0.34-0.01 ± 0.701.69 ± 0.651.30 ± 0.001.24 ± 0.282.12 ± 0.3736.3 ± 3.6228Healthy
　vs
2.78 ± 0.241.72 ± 1.033.00 ± 0.761.38 ± 0.231.41 ± 0.291.95 ± 0.4036.3 ± 3.6128BA/AD patients
0.001＊＊0.000＊＊＊0.000＊＊＊0.078†0.020＊0.099†0.987nsP (two tailed)
in developed countries throughout the world . Low
maternal anti-EBV antibody titers would result in low
titers of anti-EBV antibodies in the infant, which may
increase the risk of symptomatic EBV infection, one
of which may be an atopic disease．
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